Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Somatuline Depot Pre- and Post-Endonasal Surgery in Acromegaly
NCT01861717Phase 4Terminated
- Sponsor
- Providence Saint John's Cancer Institute
- Start
- May 2013
- Primary completion
- Jan 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lanreotide in acromegaly, sponsored by Providence Saint John's Cancer Institute. Primary endpoint: Early Remission of Acromegaly. Started May 2013; status: terminated.
02
Drugs
lanreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NCT01861717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861717.